Therapeutic antibodies

  • IIBR's Antibody engineering group developed three antibody-based therapeutics to be used against chemical and biological threat agents such as: Anthrax, ricin, organophosphates, botulinum and Tularemia.
  • LSRI filed patent applications for these antibodies, both in the US and in Israel.
  • LSRI intends to license the patent and its rights to use, to international companies for further development in clinical level​